CNS Pharmaceuticals (NASDAQ:CNSP) Earns “Hold” Rating from Maxim Group

CNS Pharmaceuticals (NASDAQ:CNSP)‘s stock had its “hold” rating restated by stock analysts at Maxim Group in a research report issued on Tuesday,Benzinga reports.

Separately, Alliance Global Partners upgraded shares of CNS Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 24th.

CNS Pharmaceuticals Trading Down 57.0 %

CNS Pharmaceuticals stock traded down $1.93 during mid-day trading on Tuesday, hitting $1.46. The stock had a trading volume of 1,977,876 shares, compared to its average volume of 263,057. CNS Pharmaceuticals has a one year low of $2.00 and a one year high of $975.00. The firm has a market capitalization of $1.67 million, a P/E ratio of -0.02 and a beta of 2.65. The firm’s 50 day moving average is $4.17 and its 200 day moving average is $5.47.

Institutional Trading of CNS Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC boosted its stake in shares of CNS Pharmaceuticals by 90.5% during the fourth quarter. Geode Capital Management LLC now owns 387,064 shares of the company’s stock valued at $47,000 after purchasing an additional 183,884 shares in the last quarter. Wealthfront Advisers LLC bought a new stake in CNS Pharmaceuticals during the fourth quarter valued at about $26,000. Integrated Wealth Concepts LLC bought a new position in shares of CNS Pharmaceuticals during the 4th quarter worth approximately $30,000. Connective Capital Management LLC acquired a new position in shares of CNS Pharmaceuticals during the fourth quarter worth $34,000. Finally, XTX Topco Ltd purchased a new stake in CNS Pharmaceuticals during the 4th quarter worth approximately $36,000. Institutional investors own 14.02% of the company’s stock.

CNS Pharmaceuticals Company Profile

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.